| State: | New York |
|---|---|
| Address: | 7 Legion Dr, Valhalla, NY 10595 |
| Zip code: | 10595 |
| Phone: | (212) 375-2694 |
| Website: | http://www.oligomerix.com/ |
Oligomerix, Inc. is located in Westchester County of New York state. On the street of Legion Drive and street number is 7. To communicate or ask something with the place, the Phone number is (212) 375-2694. You can get more information from their website.
The coordinates that you can use in navigation applications to get to find Oligomerix, Inc. quickly are 41.0738448 ,-73.7751672
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Oligomerix, Inc., use the form below and your opinion, advice or comment will appear in this space.
Oligomerix, Inc. at 7 Legion Dr, Valhalla, NY 10595. Get Oligomerix, Inc. can be contacted at (212) 375-2694. Get Oligomerix, Inc. reviews, rating, hours, phone ...
https://www.chamberofcommerce.com/united-states/new-york/valhalla/pharmaceutical-company/2015364995-oligomerix-inc/PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease ... 212-375-2694 . 917-912-4088 [email protected]
https://www.prnewswire.com/news-releases/oligomerix-inc-to-present-multiple-posters-highlighting-its-tau-focused-technology-during-the-annual-alzheimers-association-international-conference-214637941.html/PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the discovery and development of disease modifying therapeutics for Alzheimer's disease...
https://www.prnewswire.com/news-releases/oligomerix-inc-announces-addition-of-industry-veteran-james-hendrix-phd-to-serve-as-senior-director-of-chemistry-215559661.htmlCONTACTS: Oligomerix, Inc. 7 Legion Drive, Valhalla, NY Tiberend
https://www.medindia.net/health-press-release/Oligomerix-Relocates-Corporate-Headquarters-and-Secures-Additional-Laboratory-Space-from-New-York-Medical-College-196708-1.htmOligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers.
https://www.lelezard.com/en/news-2628212.htmlNEW YORK, July 15, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the discovery and development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today that James Hendrix, Ph.D., has been appointed Senior Director of Chemistry of the company.. Dr. Hendrix has more than 20 years of pharmaceutical ...
https://www.biospace.com/article/releases/oligomerix-announces-addition-of-industry-veteran-b-james-hendrix-b-ph-d-to-serve-as-senior-director-of-chemistry-/NEW YORK, Sept. 4, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the publication of a collaborative study in the peer-reviewed International Journal of Cell Biology that found tau oligomer trimers were specifically toxic to ...
https://www.biospace.com/article/releases/oligomerix-release-identification-of-a-tau-oligomer-structure-that-is-toxic-to-neurons-published-in-the-i-b-international-journal-of-cell-biology-/NEW YORK, May 22, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the completion of its Series B financing, which includes both issuance of new convertible preferred shares and warrants that would represent approximately $2.8M in new ...
https://www.inknowvation.com/sbir/story/oligomerix-inc-completes-series-b-financingNEW YORK, Sept. 10, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the receipt of a two-year Small Business Innovation Research (SBIR) Phase IIB grant for $1.7M from the National Institutes of Health (NIH), National Institute on ...
https://www.biospace.com/article/releases/oligomerix-awarded-phase-iib-grant-from-the-nih-to-discover-drugs-that-inhibit-alzheimer-s-disease-progression-/212-375-2694 [email protected] SOURCE Oligomerix, Inc. News published on 7 january 2014 at 10:17 and distributed by: Le Lézard. About Contact us. Others sections. News wire.
https://www.lelezard.com/en/news-2546692.html